How Long Do You Have to Take Prednisone for Lupus?
At a Glance
Prednisone is not intended for long-term use in systemic lupus erythematosus. Doctors prescribe it as a temporary bridge to quickly control inflammation. The goal is to slowly taper the dose to 5 mg or less per day, or stop it entirely, once safer long-term medications take effect.
Many patients diagnosed with systemic lupus erythematosus (SLE) are initially prescribed prednisone to quickly bring inflammation and disease flares under control. A common and very understandable fear is that you will need to stay on high doses of this medication forever. The good news is that current medical guidelines do not recommend long-term use of high-dose steroids. Instead, the goal of modern lupus treatment is to use prednisone as a temporary bridge to calm your immune system down, while transitioning you to other long-term medications that are safer. Over time, your doctor will work to taper (slowly decrease) your prednisone dose to the lowest possible level—ideally under 5 to 7.5 milligrams per day, or stopping it entirely [1][2][3].
The Risks and Side Effects of Prednisone
Prednisone is incredibly effective at stopping an active lupus flare, but it comes with a physical and emotional toll. In the short term, high doses (like 40 to 60 mg/day) often cause frustrating side effects such as severe weight gain, facial swelling (“moon face”), insomnia, and drastic mood swings.
Additionally, the side effects increase the longer you take it and the higher the dose. High-dose steroid use, or taking doses above 7.5 mg/day for more than six months, is linked to a higher risk of long-term organ damage [1][4]. Prolonged use can lead to issues such as:
- Bone thinning (osteopenia and osteoporosis): Over time, steroids weaken your bones, a process accelerated by low Vitamin D levels [5][6]. Talk to your doctor about whether you need a bone density (DEXA) scan, or calcium and Vitamin D supplements to protect your bones.
- Increased infection risk: Doses of prednisone above 10 mg/day significantly weaken your immune system’s ability to fight off everyday infections [7][8].
- Heart disease: Steroids can cause adverse changes in your cholesterol, increasing the risk of cardiovascular disease and plaque buildup in the arteries [9][10].
To minimize these outcomes, rheumatologists use a “steroid-sparing strategy.”
What is a Steroid-Sparing Strategy?
A steroid-sparing strategy involves introducing other medications that control your lupus just as effectively as prednisone, but without the harmful long-term side effects. By adding these medications, your doctor can safely lower your steroid dose without risking a return of your symptoms.
These medications typically fall into a few categories:
- Antimalarials: Medications like hydroxychloroquine are the foundation of lupus treatment. Taking hydroxychloroquine regularly is a key predictor of successfully coming off steroids without having a disease flare [3][11].
- Immunosuppressants: If hydroxychloroquine isn’t enough, your doctor may add immunosuppressive drugs, such as methotrexate (great for joint involvement), mycophenolate, or azathioprine. These help quiet your immune system, allowing for a steady reduction in prednisone [12].
- Targeted Biologics: More recent therapies, such as belimumab and anifrolumab, specifically target the pathways in the immune system responsible for lupus. Studies show that using these biologics can successfully reduce the need for corticosteroids [13][14].
The Process of Tapering
Tapering means slowly and systematically reducing your dose over time. You should never stop taking prednisone suddenly. If you do, you risk a dangerous condition called adrenal insufficiency (or severe steroid withdrawal), because your body needs time to adjust to producing its own natural steroids again.
The strategy for tapering usually looks like this:
- Initial Drops from High Doses: When starting on high doses (e.g., 40 mg to 60 mg/day) for a severe flare, the first dose reductions are usually larger and faster (such as dropping by 5 to 10 mg every week or two). This helps get you out of the highest-risk zone once the severe inflammation is controlled.
- Achieve Low Disease Activity: The goal is to get your lupus into remission or a Lupus Low Disease Activity State (LLDAS) using your steroid-sparing medications [3].
- Slow Reduction at Lower Doses: Once your dose is lower (around 10 mg to 7.5 mg/day) and your disease is quiet, the taper slows down drastically. Research shows that very slow tapers at this stage—such as reducing from 7.5 mg/day to zero over six months or longer—result in much better outcomes and fewer severe flares than rushing the process [3].
- The Target Dose: The ultimate goal is zero prednisone. However, for some patients, completely stopping the drug causes lupus symptoms to return. In those cases, keeping the dose at 5 mg/day or less is considered acceptable. While no steroid dose is entirely risk-free, maintaining doses under 5 mg/day greatly minimizes the risk of long-term damage compared to higher doses [2][15].
Note on flares vs. withdrawal: When dropping a dose, it is common to feel temporary aches, fatigue, or mood changes for a few days. This is often just steroid withdrawal as your body adjusts, not a return of your lupus. If the pain is severe or lasts longer than a week, contact your rheumatologist to see if it is a true lupus flare.
Common questions in this guide
Will I have to stay on prednisone forever for my lupus?
Why can't I just stop taking prednisone when I feel better?
What is a steroid-sparing strategy for lupus?
How can I tell if I am having prednisone withdrawal or a lupus flare?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What is our specific plan or timeline for tapering my current prednisone dose?
- 2.Are my other medications, such as hydroxychloroquine or immunosuppressants, currently doing enough to allow for a successful steroid reduction?
- 3.Am I a candidate for biologic therapies like belimumab to help me safely lower my steroid dose?
- 4.Should I be getting a DEXA scan or taking calcium and Vitamin D supplements to protect against bone thinning while I am on this medication?
- 5.How can I tell the difference between normal steroid withdrawal symptoms and a true lupus flare when we drop my dose?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (15)
- 1
Development of American College of Rheumatology Quality Measures for Systemic Lupus Erythematosus: A Modified Delphi Process With Rheumatology Informatics System for Effectiveness (RISE) Registry Data Review.
Bartels CM, Jorge A, Feldman CH, et al.
Arthritis care & research 2023; (75(11)):2295-2305 doi:10.1002/acr.25143.
PMID: 37165898 - 2
No Effect of Low-Dose Glucocorticoid Maintenance Therapy on Damage in SLE Patients in Prolonged Remission: A Propensity Score Analysis of the Longitudinal Lupus-Cruces-Bordeaux Inception Cohort.
Ruiz-Irastorza G, Paredes-Ruiz D, Dueña-Bartolome L, et al.
Journal of clinical medicine 2024; (13(20)) doi:10.3390/jcm13206049.
PMID: 39457999 - 3
Combination of clinical factors predicts successful glucocorticoid withdrawal in systemic lupus erythematosus (SLE): results from a multicentre, retrospective cohort study.
Katechis S, Pitsigavdaki S, Nikoloudaki M, et al.
RMD open 2025; (11(1)) doi:10.1136/rmdopen-2024-005118.
PMID: 39762120 - 4
Prednisone and long-term damage in systemic lupus erythematosus: Which is the threshold dose? A pilot study.
Danza A, Graña D, Soto E, et al.
Lupus 2022; (31(7)):880-884 doi:10.1177/09612033221093485.
PMID: 35354060 - 5
Vitamin D level in patients with systemic lupus erythematosus: its relationship to disease course and bone mineral density.
Shevchuk S, Marynych L, Malovana T, Denyshchych L
Lupus science & medicine 2023; (10(2)) doi:10.1136/lupus-2023-000968.
PMID: 37558268 - 6
Bone turnover markers in relation to vitamin D status and disease activity in adults with systemic lupus erythematosus.
Sarkissian A, Sivaraman V, Bout-Tabaku S, et al.
Lupus 2019; (28(2)):156-162 doi:10.1177/0961203318815593.
PMID: 30509154 - 7
Clinical Characteristics, Microbiological and Risk Factors of Infections in Patients With Systemic Lupus Erythematosus.
Li G, Liu X, Zhao J
Journal of community hospital internal medicine perspectives 2025; (15(1)):36-41 doi:10.55729/2000-9666.1447.
PMID: 39867159 - 8
Factors predictive of serious infections over time in systemic lupus erythematosus patients: data from a multi-ethnic, multi-national, Latin American lupus cohort.
Pimentel-Quiroz VR, Ugarte-Gil MF, Harvey GB, et al.
Lupus 2019; (28(9)):1101-1110 doi:10.1177/0961203319860579.
PMID: 31291843 - 9
Longitudinal Evaluation of Lipoprotein Variables in Systemic Lupus Erythematosus Reveals Adverse Changes with Disease Activity and Prednisone and More Favorable Profiles with Hydroxychloroquine Therapy.
Durcan L, Winegar DA, Connelly MA, et al.
The Journal of rheumatology 2016; (43(4)):745-50 doi:10.3899/jrheum.150437.
PMID: 26834214 - 10
Risk factors for cardiovascular diseases in patients with systemic lupus erythematosus: an umbrella review.
Katayama Y, Yanai R, Itaya T, et al.
Clinical rheumatology 2023; (42(11)):2931-2941 doi:10.1007/s10067-023-06608-6.
PMID: 37142864 - 11
Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus.
Petri M, Konig MF, Li J, Goldman DW
Arthritis & rheumatology (Hoboken, N.J.) 2021; (73(6)):997-1004 doi:10.1002/art.41621.
PMID: 33403833 - 12
Systemic lupus erythematosus: An approach to pharmacologic interventions.
El Hussein MT, Wong C
The Nurse practitioner 2023; (48(7)):37-46 doi:10.1097/01.NPR.0000000000000071.
PMID: 37368557 - 13
Cumulative Corticosteroid Dose Over Fifty-Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials.
van Vollenhoven RF, Petri M, Wallace DJ, et al.
Arthritis & rheumatology (Hoboken, N.J.) 2016; (68(9)):2184-92 doi:10.1002/art.39682.
PMID: 26992106 - 14
Successful use of anifrolumab in refractory cutaneous lupus erythematosus with systemic lupus erythematosus: A case report.
Ramadhan A, Troug A, Yacyshyn E, Gniadecki R
SAGE open medical case reports 2025; (13()):2050313X251350376 doi:10.1177/2050313X251350376.
PMID: 40589849 - 15
Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial.
Mathian A, Pha M, Haroche J, et al.
Annals of the rheumatic diseases 2020; (79(3)):339-346 doi:10.1136/annrheumdis-2019-216303.
PMID: 31852672
This page provides general educational information about prednisone tapering for systemic lupus erythematosus. Always consult your rheumatologist before changing or stopping your steroid dose, as sudden changes can cause serious health complications.
Get notified when new evidence is published on Systemic lupus erythematosus.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.